Vanguard Group
ACUR

Vanguard Group’s Acura Pharmaceuticals ACUR Stock Holding History

Vanguard Group’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-195,943
Closed -$150K – 4102
2016
Q4 		$150K Hold
195,943
– – ﹤0.01% 3931
2016
Q3 		$314K Sell
195,943
-5,881
-3% -$10.4K ﹤0.01% 3833
2016
Q2 		$374K Hold
201,824
– – ﹤0.01% 3837
2016
Q1 		$572K Sell
201,824
-229
-0.1% -$487 ﹤0.01% 3755
2015
Q4 		$511K Hold
202,053
– – ﹤0.01% 3825
2015
Q3 		$475K Buy
202,053
+5,966
+3% +$20.3K ﹤0.01% 3864
2015
Q2 		$967K Buy
196,087
+9,474
+5% +$39.4K ﹤0.01% 3673
2015
Q1 		$737K Hold
186,613
– – ﹤0.01% 3711
2014
Q4 		$420K Sell
186,613
-5,471
-3% -$15.1K ﹤0.01% 3780
2014
Q3 		$753K Sell
192,084
-900
-0.5% -$4.22K ﹤0.01% 3593
2014
Q2 		$1.05M Buy
192,984
+5,072
+3% +$30.7K ﹤0.01% 3469
2014
Q1 		$1.37M Buy
187,912
+10,658
+6% +$92.6K ﹤0.01% 3359
2013
Q4 		$1.48M Buy
177,254
+3,811
+2% +$32.2K ﹤0.01% 3307
2013
Q3 		$1.65M Buy
173,443
+6,900
+4% +$61K ﹤0.01% 3213
2013
Q2 		$1.57M Buy
+166,543
New +$1.88M ﹤0.01% 3153

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group's ACUR Position: Q1 2017 in Review

Vanguard Group sold out of Acura Pharmaceuticals (ACUR) in Q1 2017, closing a stake of 195,943 shares — an estimated $150K sold.

Vanguard Group first reported a position in ACUR in Q2 2013 and held it in 15 quarters. The position peaked at $1.65M in Q3 2013. 3 funds tracked by Wall St. Rank hold ACUR as of Q1 2017.

  • Vanguard Group reported no remaining Acura Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Vanguard Group sold 195,943 Acura Pharmaceuticals shares in Q1 2017, an estimated $150K.
  • Vanguard Group first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Vanguard Group's Acura Pharmaceuticals position peaked at $1.65M in Q3 2013.
  • 3 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q1 2017.

Based on Vanguard Group's 13F filing for Q1 2017, filed 12 May 2017.